Journal of Biochemistry Advance Access originally published online on August 26, 2006
Journal of Biochemistry 2006 140(4):517-524; doi:10.1093/jb/mvj181
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 The Japanese Biochemical Society.
ARTICLE |
Raised Serum Chondroitin Sulfate Epitope Level in Ovarian Epithelial Cancer
1 Thailand Excellence Centre for Tissue Engineering, Department of Biochemistry, 2 Department of Pathology, and 3 Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand; 4 Laboratory of Proteoglycan Signaling and Therapeutics, Faculty of Advanced Life Science, Hokkaido University, Frontier Research Center for Post-Genomic Science and Technology, Nishi 11-choume, Kita 21-jo, Kita-ku, Sapporo 001-0021, Japan; and 5 UK Centre for Tissue Engineering and Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences, University of Manchester, Michael Smith Building, Oxford Road, Manchester M13 9PT, United Kingdom
* To whom correspondence should be addressed. Phone: +66 053 894188, Fax: +66 053 894188, E-mail: pkongtaw{at}mail.med.cmu.ac.th
Objective: To determine the value of serum chondroitin sulfate epitope WF6 and hyaluronan (HA) levels as a biomarker for early detection of ovarian epithelial cancer and other gynecological disorders. Method: Serum WF6 CS epitope and HA were measured in 91 patients with ovarian epithelial cancer, 39 patients with non-cancer gynecological disorders and 30 healthy women. Serum chondroitin sulfate (CS) WF6 epitope was determined by a competitive immunoassay with the monoclonal antibodies WF6, which specifically recognizes an epitope in native CS chains. In addition, serum HA concentration was measured by an ELISA-based assay with a biotinylated affinity HA-binding proteins. Results: The serum concentration of CS (WF6) epitope was highly increased in epithelial types of ovarian cancer and at all stages of development (p < 0.005). Serum HA in ovarian cancer patients was significantly higher than normal controls (p < 0.05). Conclusion: These results reflect changes in ECM metabolism in progressive ovarian cancer, which cause an increase in serum CS epitopes and HA. Therefore, serum CS epitopes may provide useful biomarkers for cancers and other disorders of the ovary. Measurement of serum HA provided complementary information, which may be useful as a discriminator between benign ovarian disorders and malignant ovarian diseases.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I. Intachai, S. Krisanaprakornkit, P. Kongtawelert, S. Ong-chai, B. Buranastidporn, E. Y. Suzuki, and D. Jotikasthira Chondroitin sulphate (WF6 epitope) levels in peri-miniscrew implant crevicular fluid during orthodontic loading Eur J Orthod, September 13, 2009; (2009) cjp056v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pothacharoen, K. Kalayanamitra, S. S. Deepa, S. Fukui, T. Hattori, N. Fukushima, T. Hardingham, P. Kongtawelert, and K. Sugahara Two Related but Distinct Chondroitin Sulfate Mimetope Octasaccharide Sequences Recognized by Monoclonal Antibody WF6 J. Biol. Chem., November 30, 2007; 282(48): 35232 - 35246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. B. ten Dam, E. M.A. van de Westerlo, A. Purushothaman, R. V. Stan, J. Bulten, F. C.G.J. Sweep, L. F. Massuger, K. Sugahara, and T. H. van Kuppevelt Antibody GD3G7 Selected against Embryonic Glycosaminoglycans Defines Chondroitin Sulfate-E Domains Highly Up-Regulated in Ovarian Cancer and Involved in Vascular Endothelial Growth Factor Binding Am. J. Pathol., October 1, 2007; 171(4): 1324 - 1333. [Abstract] [Full Text] [PDF]
|
|